Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
Willis' EPA per pass play (.746) was the highest for a Packers starting quarterback in the regular season since Rodgers ...
GLP-1 usage is on the rise, and researchers are looking for other health benefits associated with the drug, including its effects on bladder health. But as GLP-1s rise in popularity, so do nicknames ...
Welcome to Culture Clinic, MedPage Today's collaboration with Northwell Health to offer a healthcare professional's take on the latest viral medical topics. Doctors performing certain medical scans on ...
XReal has launched a new entry-level AR glasses model in Japan, the XReal 1S. It slots below the XReal One Pro announced earlier this year and is the first pair of consumer AR glasses to offer ...
XREAL is wrapping up 2025 with the launch of a new entry-level AR glasses model, the XREAL 1S. It sits below the more expensive XREAL One Pro (announced in July) in the lineup and is the first in the ...
Weight-loss drugs are coming for a new kind of customer. “You don’t need to be obese to start a GLP-1,” reads an ad from a telehealth startup, the words scrawled in icing on a cake. Another one ...
When Chevese Turner first discussed Ozempic with her doctor to treat her diabetes, she was both worried and relieved. Finally, “there was something effective that [was] going to address my diabetes,” ...
The Trump administration announced its newest pharmaceutical agreement under its Most Favored Nation policy Thursday, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at ...
Medicare will begin covering weight loss drugs in 2026 for the first time under a pricing agreement announced by the White House, according to a Nov. 6 press release. The agreements with Eli Lilly and ...
Dothée is a writer in Los Angeles. On Oct. 16, President Trump promised to slash the price of brand-name GLP-1 drugs like Ozempic and Wegovy to $150 a month. Even after a top health official suggested ...